Member Info for Digger01

Share price is still subdued despite the forecast of likely interest rate drops. My only concern here, is the dominant exposure to USD receipts, with a weakens $ v GBP. Obviously the overall performance will depend a lot on their currency hedging. Excellent divi yield around 10% so, likely to still be a good LT investment.

They won’t be back to normal as we still don’t have floatation running. I am hoping that the TD wall raise news and re-start of floatation is announced at the same time to soften the blow!

Thank you Emerald, that all makes sense regarding various possible outcomes, but just disappointing that the time lines have slipped. However, I have confidence that they will get it right and hopefully this could lead to a game changer for diagnostic albeit time delayed through a Solaris lab.

As far as I can see reading RNS’s, we still haven’t had any update, even though it was promised for year end. Is this correct? Also Ovarian update also overdue?

Based on the last results it would appear that they had enough cash for circa 12 months. So either a deal or cash raise needs to come soon.

Can anyone else throw any more light on this?

Unfortunately a lack of trust based on history, over promising, under delivery and now perceived lack of control. Also concerns about potential covenant breaks, if they don’t hit targets, Hopefully this is a big kick up the proverbial snd they focus on delivery.

If so, I agree, undervalued.

Thank you 404.

I note from today’s RNS that Q2 23 produced 14.9k sales at circa 20% less selling price, so I estimate the revenue was 1.8m. Obviously licensing money/deals are presumably taken as revenue and cash (when received)

In order Not to breach lending covenant requirements, what revenue/prescriptions do we need to achieve in Q1? As far as I can see from info available, it looks like around 30-34k prescriptions required. Can any concur or offer a number?

Already FDA approved. RNS 30th June. Funding and sales required to survive.

Be careful here guys. This is likely being pushed for the next raise as this company is running it’s cash thank on empty. I have seen this before with Xbio and they WILL need cash imminently. If you catch the wave right and jump off before the break, then you may well make a few bob. I am a LTH in deep water waiting and hoping for a turnaround, but it will take some time and Money! GLA

110k shares voted no

110k shares with me voted No.

From the Interims:

It is expected that permission will be received in January 2024 provided the independent inspection reveals no defects in the wall.

News was not promised, more like targeted.

Thank you for the post Jim.

Very encouraging! I’m not sure when to expect Q4 results, as Q3 wasn’t published until Dec but hopefully the US trend continues and we might see the SP finally start to respond.

Well stated Tomo.

Angle have an excellent product but in a complicated and multi use market. Contracts are won via , market awareness, trial, results, advertising, referrals and hard work. They don’t come like selling sweets. based on the nature of the market, it cannot be easy to make cash flow projections to which the directors would be accountable. I.e. damned if you do damned if you don’t. Clearly They are trying to build a profitable and very successful business, which could help millions of people, but this is likely to be a long journey. In 2008, I invested in a pharmaceutical company called Verona Pharma (VRP) and At one stage, I thought I was going to lose all of my investment. The company had one main product with one main market. 13 years later, I finally was rewarded for my patience, albeit overextended. My investment was diluted on many occasions, but I always believed in the product. Patience is Required!

BUT solid progress must be demonstrated by the company and in this case, we are slowly seeing it.

Hopefully bigger players will see this and invest.

Thanks Tomo, I missed that one, but still a vote of confidence as far as am concerned.

Well based on the 1pm notification, these guys are happy to increase their stake, but no mention of it on this board?

Prostate results also imminent!

Data from the Prostate study must be imminent which could be a possible game changer. Last info I could find, indicated year end 2023.

There are very good reasons for the very low price, recovery and re-trace, which I am sure you are well aware of. Patience will be rewarded. Next catalyst will be news on the existing tailings dam raise and permission for the new one, followed by resumption of use of agitation plant.